Harnessing Plant Platforms for Innovative Monoclonal Antibody Production in Veterinary Medicine

Lippert Kanfer^*
*Correspondence: Lippert Kanfer, Department of Biology, Carleton University, Ottawa, ON K1S 5B6, Canada, Email:

Keywords

Monoclonal Antibodies (mAbs) • Plant biotechnology • Veterinary medicine • Plant-based platforms • Biomanufacturing • Biotechnology innovation

Introduction

Monoclonal antibodies (mAbs) are highly specific and effective therapeutic agents used extensively in human and veterinary medicine. They are produced using various platforms, with mammalian cell lines being the traditional and most widely used method. However, the high costs and complex nature of mammalian cell-based production systems have prompted researchers to seek alternative methods. Plant-based expression systems have emerged as a promising solution, offering a more cost-effective and scalable approach to mAb production. This article reviews the use of plant platforms in veterinary medicine, focusing on their benefits, current applications, and future directions [1].

Plant-based platforms utilize genetically modified plants to produce recombinant proteins, including mAbs. The process involves inserting a gene encoding the desired mAb into a plant’s genome or plastid. The transformed plants then produce the antibody during their growth cycle. Key plant systems used include N. benthamiana (tobacco) and A. thaliana, among others. Genes encoding the mAbs are introduced into the plant’s cells using techniques such as Agrobacterium-mediated transformation or viral vectors. Transformed plants are grown under controlled conditions to produce the antibody in their tissues. Antibodies are extracted from plant tissues and purified for use. Plant-based systems can significantly reduce production costs compared to mammalian cell cultures. Plants do not require expensive growth media and bioreactors. Plants can be grown in large quantities, making it easier to scale up production as needed. Plants do not harbor human pathogens, reducing the risk of contamination and enhancing the safety profile of the produced mAbs. The risk of contamination by human or animal pathogens is minimized in plant-based systems [2].

Literature Review

Plants and mammals have different glycosylation patterns, which can affect the efficacy and safety of the produced mAbs. Plant-specific glycosylation may alter antibody function or induce unwanted immune responses. The regulatory framework for plant-produced therapeutics is still evolving. Ensuring compliance with regulatory standards and demonstrating equivalence to traditional production methods can be challenging. The level of protein expression can vary between individual plants, which may affect the consistency of the product. Plant-based mAb production has shown promise in veterinary medicine, offering solutions for a range of animal health issues. Plant-derived mAbs have been explored for the development of vaccines and antiviral treatments for livestock diseases [3].

Plant-produced mAbs are being investigated for use in diagnostic assays for animal diseases, providing accurate and rapid testing methods. Continued research and development are needed to address the challenges associated with plant-based mAb production. Advances in genetic engineering, glycoengineering, and regulatory science will be crucial in optimizing plant platforms. Future work should focus on improving glycosylation profiles, ensuring regulatory compliance, and enhancing the scalability and consistency of plant-based systems. Harnessing plant platforms for monoclonal antibody production represents a significant advancement in veterinary medicine. The benefits of reduced costs, scalability, and safety make plant-based systems a compelling alternative to traditional mammalian cell-based methods. Addressing the current challenges and advancing technological capabilities will be key to unlocking the full potential of plant-based mAb production for veterinary applications [4].

Research has shown that plant-derived mAbs can be used to create vaccines for livestock diseases. For example, a study on plant-produced antibodies against Foot-and-Mouth Disease (FMD) in cattle highlighted the feasibility of using this technology for vaccine development. The antibodies produced in plants were able to neutralize the FMD virus in vitro, indicating potential for vaccine efficacy. In aquaculture, plant-derived antibodies have been employed to develop diagnostic tests for fish diseases. These tests, produced at a fraction of the cost of traditional methods, offer a practical and affordable solution for early detection and management of outbreaks in fish farms. Plant-based antibodies have been explored for treating diseases in companion animals. For instance, antibodies against canine parvovirus produced in plants have shown promise in preliminary trials, suggesting that this technology could provide effective treatments for common canine infections [5].

Discussion

To advance plant-based mAb production, collaborations between research institutions, biotechnology companies, and regulatory bodies are essential. Partnerships can facilitate technology transfer, ensure adherence to regulatory standards, and streamline the development process. Developing a robust infrastructure for plant-based production, including facilities for large-scale cultivation and processing, will be crucial. Investment in this infrastructure can help overcome the scalability challenges and ensure consistent quality. Educating veterinarians and researchers about the benefits and limitations of plant-based mAb production will be important for widespread adoption. Training programs and workshops can help build expertise and foster innovation in this emerging field. The use of genetically modified plants raises ethical questions that need to be addressed. Ensuring transparency in the development and application of plant-based mAb technologies is crucial for gaining public trust. Engaging with stakeholders and the public can help address concerns and foster acceptance. Plant-based mAb production has potential environmental benefits compared to traditional methods. Plants can be grown with less resource-intensive inputs, and the risk of biohazardous waste is reduced. However, careful management of plant cultivation and disposal practices is necessary to mitigate any potential environmental impacts. Optimization of Expression Systems: Ongoing research should focus on optimizing plant expression systems to enhance yield and quality of mAbs. Innovations in genetic engineering and plant biology can lead to more efficient and consistent production processes [6].

Conclusion

The integration of plant-based monoclonal antibody production into veterinary medicine holds significant promise for enhancing animal health care. With the advantages of cost-efficiency, scalability, and safety, plant platforms offer a viable alternative to traditional production methods. Addressing the associated challenges through ongoing research, strategic partnerships, and regulatory advancements will be key to realizing the full potential of this innovative technology. As plant-based systems continue to evolve, they are poised to make a substantial impact on veterinary therapeutics, offering new solutions for treating and preventing diseases in animals.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Mueller, Ralf S. "Update on allergen immunotherapy."Vet Clin N Am49 (2019): 1-7.

   Google Scholar, Crossref, Indexed at

2. Gober, Margaret, Andrew Hillier, Manuel A. Vasquez-Hidalgo and Deborah Amodie, et al. "Use of cytopoint in the allergic dog."Front Vet Sci 9 (2022): 909776.

   Google Scholar, Crossref, Indexed at

3. Lascelles, B. Duncan X., David Knazovicky, Beth Case and Mila Freire, et al. "A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain."BMC Vet Res 11 (2015): 1-12.

   Google Scholar, Crossref, Indexed at

4. Su, Hang, André Van Eerde, Espen Rimstad and Ralph Bock, et al. "Plant-made vaccines against viral diseases in humans and farm animals."Front Plant Sci 14 (2023): 1170815.

   Google Scholar, Crossref, Indexed at

5. Holtz, Barry R., Brian R. Berquist, Lindsay D. Bennett and Vally JM Kommineni, et al. "Commercial‐scale biotherapeutics manufacturing facility for plant‐made pharmaceuticals."Front Plant Sci 13 (2015): 1180-1190.

   Google Scholar, Crossref, Indexed at

6. Hiatt, Andrew, Robert Caffferkey and Katherine Bowdish. "Production of antibodies in transgenic plants."Nature342 (1989): 76-78.

   Google Scholar, Crossref, Indexed at